Julie Nangia, MD, talks with Erika Hamilton, MD, about the results of the HER2CLIMB-05 study, a Phase III trial that demonstrated that adding tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Results from the Phase III HER2CLIMB-05 Trial
Join the global breast cancer community for four days of research spanning experimental biology, etiology, translational science, prevention, diagnosis and treatment, December 8-11 in San Antonio, Texas.
Share: